Holen Sie sich die Stockscreener-App
19.50
1.83%
0.35
Handel nachbörslich:
19.50
Schlusskurs vom Vortag:
$19.15
Offen:
$18.73
24-Stunden-Volumen:
148.33K
Relative Volume:
2.41
Marktkapitalisierung:
$210.41M
Einnahmen:
$19.85M
Nettoeinkommen (Verlust:
$-12.75M
KGV:
-14.13
EPS:
-1.38
Netto-Cashflow:
$-21.94M
1W Leistung:
-2.84%
1M Leistung:
+8.39%
6M Leistung:
+11.56%
1J Leistung:
+58.28%
1-Tages-Spanne:
$18.73
$19.73
1-Wochen-Bereich:
$18.73
$20.19
52-Wochen-Spanne:
$11.04
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Vergleichen Sie MDWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
19.50 | 210.41M | 19.85M | -12.75M | -21.94M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-16 | Bestätigt | Maxim Group | Buy |
| 2022-12-22 | Eingeleitet | Maxim Group | Buy |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-09-23 | Eingeleitet | BTIG Research | Buy |
| 2016-11-28 | Eingeleitet | Aegis Capital | Buy |
| 2016-08-17 | Eingeleitet | Wells Fargo | Outperform |
| 2014-04-16 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Mediwound Ltd Aktie (MDWD) Neueste Nachrichten
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Exclusive: MediWound CEO to Reveal Latest Tissue Repair Innovations at Major Healthcare Conference - StockTitan
JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week - Yahoo Finance
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? - Yahoo Finance
Barclays PLC Increases Stock Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
Burns Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | MediWound, Kaken Pharma, Kerecis, Medline, Mallinckrodt Pharma, Avita Medical, Vericel Corp - The Globe and Mail
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound (NASDAQ:MDWD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions - Yahoo Finance
MediWound Ltd.'s (NASDAQ:MDWD) P/S Still Appears To Be Reasonable - Simply Wall St
Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD) - Defense World
Barclays PLC Raises Stake in MediWound Ltd. (NASDAQ:MDWD) - Defense World
When (MDWD) Moves Investors should Listen - Stock Traders Daily
State Street Corp Raises Holdings in MediWound Ltd. (NASDAQ:MDWD) - Defense World
State Street Corp Purchases 45,529 Shares of MediWound Ltd. (NASDAQ:MDWD) - MarketBeat
MediWound (NASDAQ:MDWD) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
Learn to Evaluate (MDWD) using the Charts - Stock Traders Daily
We're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn Rate - Yahoo Finance
Charles Schwab Investment Management Inc. Decreases Position in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement - TipRanks
MediWound to Host Virtual Key Opinion Leader Event to - GlobeNewswire
MediWound Announces Expert Panel Event: Phase III Trial Plans for Revolutionary Wound Treatment EscharEx - StockTitan
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future - Yahoo Finance
(MDWD) Long Term Investment Analysis - Stock Traders Daily
MetLife Investment Management LLC Acquires New Shares in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MDWD (MediWound) Price-to-Operating-Cash-Flow : (As of Dec. 02, 2024) - GuruFocus.com
FY2024 EPS Estimates for MediWound Lowered by HC Wainwright - MarketBeat
Brokers Offer Predictions for MediWound FY2024 Earnings - Defense World
MediWound (FRA:M8W) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
HC Wainwright Cuts MediWound (NASDAQ:MDWD) Price Target to $25.00 - MarketBeat
MediWound Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
MediWound Advances Enzymatic Therapeutics Amid Financial Shifts - TipRanks
Mediwound earnings missed by $0.53, revenue fell short of estimates - Investing.com Australia
MediWound: Q3 Earnings Snapshot - The Washington Post
Earnings call: MediWound shows progress in Q3 with FDA nod for NexoBrid - Investing.com
MediWound Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update - The Manila Times
MediWound Q3 Revenue Falls to $4.4M Despite NexoBrid FDA Approval; Cuts 2024 Guidance | MDWD Stock News - StockTitan
Finanzdaten der Mediwound Ltd-Aktie (MDWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.02%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):